Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice

M. Sebastian; F. Barlesi; R. Califano; A. S. Mansfield; F. H. Blackhall; E. M. Flahavan; J. Davies; P. Arnold; S. Morris; M. Reck

doi:10.1093/annonc/mdz071.006

Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice

M. Sebastian, F. Barlesi, R. Califano, A. S. Mansfield, F. H. Blackhall, E. M. Flahavan, J. Davies, P. Arnold, S. Morris, M. Reck

Medical Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	ii24
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	30
DOIs	https://doi.org/10.1093/annonc/mdz071.006
State	Published - Apr 1 2019

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdz071.006

Cite this

Sebastian, M., Barlesi, F., Califano, R., Mansfield, A. S., Blackhall, F. H., Flahavan, E. M., Davies, J., Arnold, P., Morris, S., & Reck, M. (2019). Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice. Annals of oncology : official journal of the European Society for Medical Oncology, 30, ii24. https://doi.org/10.1093/annonc/mdz071.006

Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice. / Sebastian, M.; Barlesi, F.; Califano, R. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, 01.04.2019, p. ii24.

Research output: Contribution to journal › Article › peer-review

Sebastian, M, Barlesi, F, Califano, R, Mansfield, AS, Blackhall, FH, Flahavan, EM, Davies, J, Arnold, P, Morris, S & Reck, M 2019, 'Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 30, pp. ii24. https://doi.org/10.1093/annonc/mdz071.006

Sebastian M, Barlesi F, Califano R, Mansfield AS, Blackhall FH, Flahavan EM et al. Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Apr 1;30:ii24. doi: 10.1093/annonc/mdz071.006

Sebastian, M. ; Barlesi, F. ; Califano, R. et al. / Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2019 ; Vol. 30. pp. ii24.

@article{6df8f530fc1f46dfb1b6f0ae375cc939,

title = "Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice",

author = "M. Sebastian and F. Barlesi and R. Califano and Mansfield, {A. S.} and Blackhall, {F. H.} and Flahavan, {E. M.} and J. Davies and P. Arnold and S. Morris and M. Reck",

year = "2019",

month = apr,

day = "1",

doi = "10.1093/annonc/mdz071.006",

language = "English (US)",

volume = "30",

pages = "ii24",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice

AU - Sebastian, M.

AU - Barlesi, F.

AU - Califano, R.

AU - Mansfield, A. S.

AU - Blackhall, F. H.

AU - Flahavan, E. M.

AU - Davies, J.

AU - Arnold, P.

AU - Morris, S.

AU - Reck, M.

PY - 2019/4/1

Y1 - 2019/4/1

UR - http://www.scopus.com/inward/record.url?scp=85079689856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079689856&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz071.006

DO - 10.1093/annonc/mdz071.006

M3 - Article

C2 - 32131195

SN - 0923-7534

VL - 30

SP - ii24

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this